At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
TAK-906 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-906 in Japanese Healthy Male Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-906 and TAK-906 Placebo for Japanese Healthy Adult Male Participants. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of TAK-906 in Japanese healthy male participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Healthy Adult Male Participants
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartAug 2017
Primary CompletionOct 2017
TodayJul 2026
First PostedAug 2, 2017
Enrollment StartAug 7, 2017
Primary CompletionOct 7, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.9 years ago
Interventions
TAK-906drug
TAK-906 capsules.
TAK-906 Placebodrug
Placebo capsules.